This is supported by the
PEACE (Prevention of Events With Angiotensin Converting
Enzyme Inhibition) trial in patients with stable
CHD (55% of whom had previous MI) and normal systolic
function, in which elevated levels of hsTnT (>1 ng/l) had
a strong and graded association with the risk of both CVD
and heart failure but not MI (4).